{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:52:25Z","timestamp":1790013145353,"version":"4.0.1"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the cost-effectiveness of dual-agent group (finotonlimab combined with a bevacizumab biosimilar) (SCT510) versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HCC) from the perspective of the Chinese healthcare system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on the results of a Phase III clinical trial, a three-state partitioned survival model was constructed. The primary outcomes of the model included total costs, total quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER). Cost-effectiveness analysis was employed to evaluate the economic efficiency of the dual-agent group compared to the sorafenib group as first-line treatment for advanced HCC. The model cycle length was set at 3 weeks, with a time horizon of 10 years and a discount rate of 4.5%. The willingness-to-pay (WTP) threshold was set at three times China\u2019s 2025 per capita gross domestic product (GDP) (299,400 CNY). One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to assess the robustness of the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ICER for the dual-agent group compared to the sorafenib group, calculated based on QALYs, was 859,053.76 CNY\/QALY, which is higher than the WTP threshold (299,400 CNY). One-way sensitivity analysis indicated that parameters such as utility value in the PD state, utility value in the PFS state, the cost of finotonlimab and bevacizumab biosimilar had a significant impact on the ICER, while other parameters had minimal influence. The base-case analysis results were robust. Probabilistic sensitivity analysis showed that at a WTP threshold of 299,400 CNY, the probability of the dual-agent group being cost-effective was 0%. When the WTP threshold was approximately 842,000 CNY, the two groups had equal probability of being cost-effective. The probabilistic sensitivity analysis results were consistent with the base-case analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>From the perspective of the Chinese healthcare system, finotonlimab combined with a bevacizumab biosimilar is not cost-effective as first-line treatment for advanced HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0349044","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:39:41Z","timestamp":1778780381000},"page":"e0349044","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma"],"prefix":"10.1371","volume":"21","author":[{"given":"XueYin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiangHua","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShaoQing","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7817-7971","authenticated-orcid":true,"given":"PanFeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"3","key":"pone.0349044.ref001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"F Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"pone.0349044.ref002","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"B Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"issue":"9","key":"pone.0349044.ref003","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2174\/0109298665330781240830042601","article-title":"Association between Higher Expression of Vav1 in Hepatocellular Carcinoma and Unfavourable Clinicopathological Features and Prognosis","volume":"31","author":"W Ye","year":"2024","journal-title":"Protein Pept Lett"},{"issue":"10","key":"pone.0349044.ref004","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2174\/0109298665411024251015093155","article-title":"Evaluation of the Anti-Liver Cancer Activity of Protein Fractions Isolated from Adenium obesum Leaf Extract","volume":"32","author":"A Hajinourmohammadi","year":"2025","journal-title":"Protein Pept Lett"},{"issue":"1","key":"pone.0349044.ref005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/0113892029273682240111052317","article-title":"Analysis of the Expression of PRDX6 in Patients with Hepatocellular Carcinoma and its Effect on the Phenotype of Hepatocellular Carcinoma Cells","volume":"25","author":"R Mu","year":"2024","journal-title":"Curr Genomics"},{"issue":"7","key":"pone.0349044.ref006","first-page":"366","article-title":"Demographic and survival characteristics of untreated hepatocellular carcinoma patients: insights into the natural history and prognostic determinants","volume":"117","author":"H Gonz\u00e1lez-S\u00e1nchez","year":"2025","journal-title":"Rev Esp Enferm Dig"},{"key":"pone.0349044.ref007","doi-asserted-by":"crossref","unstructured":"Chen W, Zheng R, Baade PD. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","DOI":"10.3322\/caac.21338"},{"issue":"5","key":"pone.0349044.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(18)30127-X","article-title":"Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries","volume":"6","author":"H Zeng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"pone.0349044.ref009","article-title":"Upregulation of miR-3130-5p enhances hepatocellular carcinoma growth by suppressing ferredoxin 1: miR-3130-5p enhances HCC growth via inhibiting FDX1","volume":"17","author":"W Xu","year":"2024","journal-title":"Current Molecular Pharmacology"},{"key":"pone.0349044.ref010","article-title":"Decoding Glycobiomarkers in Non-Alcoholic Steatohepatitis (NASH) and Related Hepatocellular Carcinoma (HCC)","volume":"22","author":"S Bansal","year":"2024","journal-title":"CP"},{"issue":"18","key":"pone.0349044.ref011","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.2174\/0115701808352454241115065851","article-title":"Bioinformatic Analysis and Molecular Docking to Elucidate the Anticancer Effect of Silver Nanoparticles in Hepatocellular Carcinoma","volume":"21","author":"F Martinez-Esquivias","year":"2024","journal-title":"LDDD"},{"issue":"11","key":"pone.0349044.ref012","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2174\/1570180820666230601113529","article-title":"Analysis of the Safety and Effectiveness of Lenvatinib + TACE-HAIC + PD-1 Inhibitor for Intermediate and Advanced Hepatocellular Carcinoma","volume":"21","author":"Y Yang","year":"2024","journal-title":"LDDD"},{"issue":"4","key":"pone.0349044.ref013","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"JM Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0349044.ref014","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1478-3231.2008.01762.x","article-title":"Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model","volume":"29","author":"RS Finn","year":"2009","journal-title":"Liver Int"},{"issue":"20","key":"pone.0349044.ref015","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"RS Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0349044.ref016","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S2468-1253(25)00059-7","article-title":"Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial","volume":"10","author":"Y Shi","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"pone.0349044.ref017","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/0115665232301878240627051455","article-title":"Knockdown of hsa_circ_0102231 impedes the progression of liver cancer through the miR-873\u2013SOX4 axis","volume":"25","author":"J Qian","year":"2025","journal-title":"Current Gene Therapy"},{"key":"pone.0349044.ref018","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429310703240823045808","article-title":"Mechanism, potential, and concerns of immunotherapy for hepatocellular carcinoma and liver transplantation","volume":"17","author":"B Sensi","year":"2024","journal-title":"Curr Mol Pharmacol"},{"issue":"01","key":"pone.0349044.ref019","first-page":"16","article-title":"Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma (2023 version)","volume":"31","author":"The Chinese Chapter of the International Hepato-Pancreato-Biliary Association, Group of Liver Surgery, Surgical Society of Chinese Medical Association, Expert Committee on Liver Cancer","year":"2023","journal-title":"Chinese Journal of Hepatology"},{"issue":"8","key":"pone.0349044.ref020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"B Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0349044.ref021","doi-asserted-by":"crossref","first-page":"104782","DOI":"10.1016\/j.cellimm.2023.104782","article-title":"Antitumor activity of pegylated human interferon \u03b2 as monotherapy or in combination with immune checkpoint inhibitors via tumor growth inhibition and dendritic cell activation","author":"R Wang","year":"2023","journal-title":"Cell Immunol"},{"issue":"1","key":"pone.0349044.ref022","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41392-025-02333-5","article-title":"Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2\/3 trial","volume":"10","author":"C Zhao","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"pone.0349044.ref023","first-page":"581","article-title":"Guideline of diagnosis and treatment of primary liver cancer","volume":"32","author":"Department of Medical Administration NHC of the PRC","year":"2024","journal-title":"Journal of Multidisciplinary Cancer"},{"key":"pone.0349044.ref024","volume-title":"China guidelines for pharmacoeconomic evaluation","author":"J Wu","year":"2025"},{"key":"pone.0349044.ref025","doi-asserted-by":"crossref","first-page":"1019826","DOI":"10.3389\/fphar.2022.1019826","article-title":"Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer","volume":"13","author":"M You","year":"2022","journal-title":"Front Pharmacol"},{"issue":"10","key":"pone.0349044.ref026","first-page":"1492","article-title":"Cost-effectiveness analysis of durvalumab combined with tremelimumab in the first-line treatment of advanced hepatocellular carcinoma","volume":"42","author":"QP Chen","year":"2023","journal-title":"Herald of Medicine"},{"issue":"22","key":"pone.0349044.ref027","first-page":"2761","article-title":"Cost-utility analysis of pembrolizuman in the second-line treatment of advanced hepatocellular carcinoma based on two models","volume":"32","author":"R Meng","year":"2021","journal-title":"China Pharmacv"},{"key":"pone.0349044.ref028","doi-asserted-by":"crossref","first-page":"17588359241274625","DOI":"10.1177\/17588359241274625","article-title":"Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma","volume":"16","author":"W Liao","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"pone.0349044.ref029","volume-title":"Report on nutrition and chronic disease status of chinese residents","author":"Commission PNHaS","year":"2020"},{"issue":"18","key":"pone.0349044.ref030","first-page":"2258","article-title":"Optimization of cost-utility analysis with equal value of life-year gained: a case study of RAS-mutant metastatic colorectal cancer","volume":"35","author":"Z Hu","year":"2024","journal-title":"China Pharmacy"},{"key":"pone.0349044.ref031","doi-asserted-by":"crossref","first-page":"1411571","DOI":"10.3389\/fphar.2024.1411571","article-title":"Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China","volume":"15","author":"Z Xiang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"8","key":"pone.0349044.ref032","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2217\/cer-2020-0041","article-title":"Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis","volume":"9","author":"H Cai","year":"2020","journal-title":"J Comp Eff Res"},{"key":"pone.0349044.ref033","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13014-016-0644-4","article-title":"Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma","volume":"11","author":"HWC Leung","year":"2016","journal-title":"Radiat Oncol"},{"issue":"19","key":"pone.0349044.ref034","first-page":"2383","article-title":"Pharmacoeconomic evaluation of trastuzumab deruxtecan versus chemotherapy in the second-line treatment of advanced breast cancer with HER-2 low expression","volume":"35","author":"X Li","year":"2024","journal-title":"China Pharmacy"},{"key":"pone.0349044.ref035","doi-asserted-by":"crossref","first-page":"1264417","DOI":"10.3389\/fonc.2023.1264417","article-title":"Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma","volume":"13","author":"C-Y Tseng","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"pone.0349044.ref036","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1007\/s12325-022-02079-4","article-title":"Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma","volume":"39","author":"T Zhou","year":"2022","journal-title":"Adv Ther"},{"key":"pone.0349044.ref037","doi-asserted-by":"crossref","first-page":"778505","DOI":"10.3389\/fphar.2022.778505","article-title":"Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis","volume":"13","author":"Y Peng","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0349044.ref038","doi-asserted-by":"crossref","first-page":"891008","DOI":"10.3389\/fphar.2022.891008","article-title":"Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis","volume":"13","author":"L Li","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:39:52Z","timestamp":1778780392000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349044"}},"subtitle":[],"editor":[{"given":"Jincheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0349044","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}